TWINLAB CONSOLIDATED HOLDINGS, INC.
Healthcare · Medicinal Chemicals & Botanical Products · NV · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $11.7M | $13.6M | $17.2M | $72.1M | $66.3M | $73.5M |
| Operating income | −$1.8M | −$1.4M | −$1.8M | −$7.7M | −$5.4M | −$38.8M |
| Net income | −$9.5M | −$13.7M | −$8.2M | −$14.9M | −$14.4M | −$44.5M |
| Total assets | $6.0M | $9.0M | $20.9M | $24.9M | $35.0M | $30.4M |
| Total liabilities | $154.5M | $148.0M | $146.2M | $142.0M | $137.1M | $118.1M |
| Equity | −$148.5M | −$139.0M | −$125.3M | −$117.1M | −$102.1M | −$87.8M |
| EPS (diluted) | $-0.04 | $-0.05 | $-0.03 | $-0.06 | $-0.06 | $-0.18 |
| Shares out. | 259.1M | 259.1M | 259.1M | 393.9M | 392.1M | 255.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −15.2%
- Net margin
- −81.4%
- Return on equity
- 6.4%
- Return on assets
- −157.7%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 2566.0%
- Debt / equity
- —
- Book value / share
- $-0.57
- Revenue growth (YoY)
- −14.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -371.70distress
- Accruals / assets
- −153.2%clean
- Beneish M-Score
- -9.95normal
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 5 warning● 1 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 30, 2021
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2020
- NT 10-Qmissed a reporting deadline ↗Jun 29, 2020
- NT 10-Kmissed a reporting deadline ↗May 14, 2020
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2019
- NT 10-Kmissed a reporting deadline ↗Apr 2, 2019
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Akretive Holdings LlcActivist (13D)Apr 24, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Material events
SEC Form 8-K · most recent- Director / officer changeNov 28, 2023
- Director / officer changeMar 16, 2023
- Director / officer changeFeb 14, 2023
- Director / officer changeFeb 14, 2023
- Director / officer changeDec 12, 2022
- Director / officer changeSep 26, 2022
- Other material eventMar 17, 2022
- Director / officer changeOct 7, 2021
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-KMar 3, 2026
- 10-QOct 16, 2025
- SCHEDULE 13D/AApr 24, 2025
- 4PRIMARY DOCUMENTApr 23, 2025
- 10-QAug 1, 2024
- 10-QMay 9, 2024
- 10-KFORM 10-KMar 19, 2024
- 8-KFORM 8-KNov 28, 2023
- 10-QNov 14, 2023
- 10-QAug 14, 2023
- 10-QApr 24, 2023
- 10-KFORM 10-KMar 31, 2023
- 8-KFORM 8-KMar 16, 2023
- 8-KFORM 8-KFeb 14, 2023
- 8-KFORM 8-KFeb 14, 2023